We conducted a genome-wide association study to discover genetic variants associated with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). We genotyped 502 HCC cases and 749 non-HCC controls using the Axiom-CHB genome-wide array. After identifying single-nucleotide polymorphism clusters located in the human leukocyte antigen (HLA) region which were potentially associated with HCC, HLA-DQB1 genotyping was performed to analyze 994 anti-HCV seropositives collected in the period 1991-2013 in a community-based cohort for evaluating long-term predictability of HLA variants for identifying the risk of HCC. Cox proportional hazards models were used to estimate the hazard ratios and 95% confidence intervals of HLA genotypes for determining the aforementioned HCC risk. Eight single-nucleotide polymorphisms in the proximity of HLA-DQB1 were associated with HCC (P < 8.7 3 10 28 ) in the genome-wide association study. Long-term follow-up showed a significant association with HLA-DQB1*03:01 and DQB1*06:02 (P < 0.05). The adjusted hazard ratios associated with HCC were 0.45 (0.30-0.68) and 2.11 (1.34-3.34) for DQB1*03:01 and DQB1*06:02, respectively. After stratification by HCV genotypes, DQB1*03:01 showed protective effects only in patients with HCV genotype 1, whereas DQB1*06:02 conferred risk of HCC only in patients with HCV non-1 genotypes. HLA imputation analyses revealed that HLA-DRB1*15:01, which is in linkage disequilibrium with DQB1*06:02, also increased the risk of HCC (odds ratio, 1.96; 95% confidence interval, 1.31-2.93). Haplotype analysis supported that DQB1*03:01 and DQB1*06:02 are primarily protective and susceptible variants, respectively. Conclusion: HLA-DQB1 was independently associated with HCC; HCV genotypes modified the effects of HLA-DQB1 on the risk of HCC. (HEPATOLOGY 2018;67:651-661). H epatitis C virus (HCV) infection is prevalent in more than 130 million to 170 million persons worldwide, and HCV seroprevalence has a widespread geographic distribution, ranging from <1% to >10%.
H epatitis C virus (HCV) infection is prevalent in more than 130 million to 170 million persons worldwide, and HCV seroprevalence has a widespread geographic distribution, ranging from <1% to >10%. (1, 2) More than 50% of patients with HCV infection were reported to be living in Asia and western Pacific regions, (1) which are highly populated and experience the greatest HCV disease burden worldwide. Chronic HCV infection may increase the risk of end-stage liver diseases (3) and pose a considerable health burden. (4) However, the clinical outcomes of HCV infection markedly vary in patients.
Approximately 70% of patients with HCV infection may develop chronic hepatitis, and 20%-30% may develop cirrhosis; but others may remain asymptomatic for several decades. (5) Those with European ancestry were reported to have a higher probability of experiencing spontaneous clearance of HCV RNA than did those with African ancestry. (6) In women with HCV infection who received contaminated anti-D immunoglobulin, significant variations in clinical outcomes could not be explained by virus genotype, inoculum size, or age at infection alone. (7) Evidence suggests that the host genetic background contributes to the marked variability in clinical outcomes in patients with HCV infection. (6, 7) A genome-wide association study (GWAS) entails testing common variants across the human genome for determining associations with some phenotypes and disease susceptibility. This type of approach has been highly successful in determining genetic variants associated with antiviral treatment responses (8) (9) (10) and adverse effects during treatment (11, 12) in patients with chronic hepatitis C. Two GWASs have identified single-nucleotide polymorphisms (SNPs) associated with HCV-related hepatocellular carcinoma (HCC). (13, 14) However, hepatocarcinogenesis is a multistage process and involves multiple genetic variants. (15) Whether there exist additional genetic variants associated with HCV-related HCC warrants investigation.
Although HCV treatment has markedly progressed, discovering genetic variants associated with HCC susceptibility may facilitate the efficient targeting of surveillance efforts to high-risk patients. In addition, the variants can be used for identifying patients prioritized to receive novel expensive antiviral agents. This study explored genetic variants associated with the risk of HCC in patients with HCV infection. Moreover, this prospective study evaluated the long-term predictability of genetic variants and the aforementioned risk.
Patients and Methods

STUDY DESIGN
All of the study subjects were seropositive for anti-HCV but seronegative for hepatitis B surface antigen (HBsAg). The study applied two designs: a casecontrol and a prospective design. Figure 1 shows the study flowchart. In the first stage, a genome-wide SNP array was used to compare 502 HCC cases with 749 non-HCC controls for exploring HCC-associated SNPs. The HCC cases were enrolled from the Taiwan Liver Cancer Network (TLCN) and the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis C Virus (REVEAL-HCV) cohort; both populations are described as follows. We derived 378 HCC cases from the TLCN and 124 incident HCC cases from the REVEAL-HCV cohort. Participants in the REVEAL-HCV cohort who did not experience HCC during 1991-2013 were considered controls. Eight SNPs near the human leukocyte antigen (HLA) variant HLA-DQB1 were significantly associated with HCC after statistical corrections. In the second stage, we included 16,000 non-HCC participants from the Taiwan Biobank as controls and 669 HCC cases from the TLCN for further replication. Finally, we examined the HLA-DQB1 genotypes and evaluated the associated risk of HCC development after long-term follow-up. The details of the participants are described in the Supporting Information.
STUDY POPULATION
REVEAL-HCV Cohort
The enrollment and follow-up procedures of the present community-based cohort have been described. (16, 17) Among 23,820 participants living in seven townships in Taiwan, 1,095 were seropositive for anti-HCV but seronegative for HBsAg at study entry. All participants provided written informed consent for interview, health examination, and blood collection processes. Data were retrieved regarding sociodemographic characteristics, diet, cigarette smoking, alcohol consumption, and history of major diseases. Blood samples were obtained from each participant using disposable needles and vacuum syringes. Serum samples were fractionated within 6 hours of collection and stored at 2708C until analyses. All participants were free of HCC at study entry. The study protocol was approved by the institutional review board of the College of Public Health, National Taiwan University, and National Yang-Ming University, Taipei, Taiwan.
New HCC cases were identified by conducting follow-up health examinations and computerized linkage with National Cancer Registration profiles from January 1, 1991, to December 31, 2013. To ensure complete ascertainment, computerized linkage with National Death Certification profiles was also performed to identify deaths from HCC. HCC cases were confirmed by (1) histopathology, (2) two imaging techniques (abdominal ultrasonography and angiography or computed tomography), or (3) an imaging technique plus a serum a-fetoprotein level of 400 ng/mL or higher.
TLCN
The TLCN is a biobank containing samples of patients with HCC from major medical centers in Taiwan, and the samples can be considered to represent all HCC cases in Taiwan. Patients were diagnosed in the medical centers and invited to provide informed consent for the collection and storage of their biological specimens as well as epidemiological and virological information. All sample collection and transportation procedures were standardized, and samples were stored at 2808C until further analyses. (18, 19) 
Taiwan Biobank
The Taiwan Biobank is an approved public biobank, which enrolled subjects in the general population in Taiwan. They collected questionnaire data on personal information, biochemical tests on blood and urine, and biological specimens of DNA, plasma, and urine. To date, they have collected information from 16,000 subjects. All of the subjects have undergone whole-genome SNP genotyping. Participants from the Taiwan Biobank were included as normal controls in the general population for the replication phase. Among the 16,000 subjects, 429 were seropositive for anti-HCV.
SNP GENOTYPING
Human genomic DNA was extracted from peripheral blood leukocytes using a standard method. In the discovery phase, we genotyped 1,251 samples using the Axiom-CHB genome-wide array comprising 642,832 SNPs. All of the samples in our study had a call rate 97%. SNP quality control was followed: SNP call rate <97%, minor allele frequency <0.01, and violation of Hardy-Weinberg equilibrium (P < 10 -4 ) were excluded for subsequent analyses. Finally, 576,032 SNPs on the autosomal chromosomes were included in the subsequent analyses. In the replication phase, eight additional SNPs were genotyped for 669 HCC cases in the TLCN using the TaqMan genotyping assay (Applied Biosystems).
HLA GENOTYPING
To evaluate the HLA polymorphisms and associated risk of HCC, we enrolled 994 participants in the REVEAL-HCV cohort who had qualified genomic DNA samples and examined their HLA genotypes according to the manufacturer's instructions. The Luminex Multi-Analyte Profiling System and WAKFlow HLA typing kits (Wakunaga, Hiroshima, Japan) were used to type HLA-DQB1 loci at four-digit resolution. Briefly, the test was based on polymerase chain reaction target amplification, hybridization of the amplified products to sequence-specific oligonucleotide probes immobilized on color-coded microbeads, and detection of probe-bound amplified products.
IMPUTATION ANALYSIS OF HLA CLASS I AND CLASS II ALLELES
Imputation methodologies have been developed to predict HLA genotypes based on multiple SNPs in the proximity of HLA regions, which has enabled fine mapping of association signals in the complex region. In this study, SNP information was extracted from an extended major histocompatibility complex region ranging from 25,759,242 to 33,534,827 bp based on hg19 positions. HLA imputations were carried out using HIBAG R package software. (20, 21) Four-digit HLA imputations were carried out on HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, and HLA-DPB1 using HIBAG Asian reference. (20) Postimputation quality control of call threshold >0.5 was applied to remove poorly imputed HLA alleles. Among the HLA genes imputed, it showed 95.2%-99.5% accuracy after being verified using the Luminex Multi-Analyte Profiling System and WAKFlow HLA typing kits. (20) 
STATISTICAL METHODS
A significant threshold of P < 8.7 3 10 -8 was considered to be associated with HCC in the GWAS by Bonferroni correction. The 2log 10 (P value) was graphically plotted for all SNPs that passed the quality control filtering process in a Manhattan plot. A quantile-quantile plot obtained using the results of the allelic test revealed the inflation factor to be 1.056, indicating a low probability of false-positive associations resulting from population stratification. We applied the R statistical environment version and PLINK for the analyses; LocusZoom (http://csg.sph. umich.edu/locuszoom/) was employed for regional plots.
To evaluate HLA-DQB1 alleles and their associations with HCC, we compared the distributions of various DQB1 alleles in the cases and controls after false discovery rate correction. Alleles with a frequency <1% were combined as rare alleles. We elucidated the long-term associations between HLA-DQB1 and HCC risk. The person-years of the follow-up process were calculated for each patient as the time of enrollment to the occurrence of HCC, death, or December 31, 2013, whichever occurred first. Incidence rates of HCC per 100,000 person-years were calculated by dividing the number of new HCC cases by the personyears of the follow-up process. Kaplan-Meier curves were used to depict cumulative risks of HCC according to follow-up years, and the significance of their differences was assessed using log-rank tests. Cox proportional hazards models were used to determine the associations of new HCC cases with HLA-DQB1 after adjustment for age, sex, cigarette smoking, alcohol consumption, and serum levels of alanine aminotransferase (ALT) and HCV RNA. Hazard ratios (HRs) with 95% confidence intervals were estimated to assess the magnitude of the associations between HLA-DQB1 and HCC. The proportionality assumption of the Cox models was examined, and it was not violated. Analyses were performed using the SAS statistical software package (version 9.4; SAS Institute Inc., Cary, NC).
Results
GWAS FOR HCV-RELATED HCC
A whole-genome scan was performed on 502 cases and 749 non-HCC controls. The heritability variance for HCC among our HCV-infected subjects was 0.76. The Manhattan plot revealed an association between a cluster of SNPs located on chromosome 6 and HCC. Eight SNPs had P < 8.7 3 10 28 , suggesting the necessity of further validating these SNPs (Fig. 2) . In the replication phases, we compared 16,000 non-HCC controls from the general population with 669 HCC cases from the TLCN. Seven SNPs remained significantly associated with HCC (P < 0.0001), with the corresponding odds ratios ranging from 1.27 (1.14-1.43) to 3.22 (2.87-3.61). Among the 16,000 non-HCC controls in the Taiwan Biobank, 429 were seropositive for anti-HCV. We compared the 669 HCC cases with 429 controls, and the seven SNPs of the TLCN cases remained significantly different from those of the controls (P < 0.05) ( Table 1) . A metaanalysis that combined two stages with subjects seropositive for anti-HCV revealed that all of the eight SNPs were significantly associated with HCC (P < 0.0001), with odds ratios ranging from 1.36 (1.20-1.54) to 2.68 (2.32-3.09). Table 1 lists eight SNPs that were located in the HLA-DQB1 locus. The frequency of the eight SNPs is displayed in Supporting Table S1 .
HLA-DQB1 LOCUS AND THE ASSOCIATED RISK OF HCC
We identified 13 alleles on the HLA-DQB1 locus with an allele frequency >1% in our study population. The HLA-DQB1 allele frequencies were compared between cases and controls. After corrections for multiple testing, the distributions of HLA-DQB1*03:01 and DQB1*06:02 differed significantly between HCC cases and controls, with corrected P values of 0.001 and 0.034, respectively (Supporting Table S2 ). We also performed direct genotyping of HLA-DPB1. However, there were no significant associations between HLA-DPB1 and HCC (Supporting Table  S3 ).
CUMULATIVE RISK OF HCC BY HLA-DQB1 ALLELES
After 18,703 person-years of follow-up, 141 new HCC cases were reported in our study population, yielding an HCC incidence of 754 per 100,000 person-years. Figure 3 shows the cumulative risk of HCC stratified by DQB1*03:01 and DQB1*06:02. DQB1*06:02 conferred an increased risk of HCC, with a cumulative risk of 30.7% after long-term follow-up (P < 0.001). In contrast, the cumulative risk of HCC was 11.0% for DQB1*03:01 and 23.4% for other genotypes (P < 0.001); we determined 5.3% and 33.9% of our study population to be homozygous and heterozygous for DQB1*03:01, respectively. The risk of HCC did not vary significantly in the homozygous 
HLA-DQB1, HCV GENOTYPES, AND THE ASSOCIATED RISK OF HCC
There were 334 patients with HCV genotype 1 and 255 with HCV genotype non-1 infection. Table 2 shows the HRs of DQB1*03:01 and DQB1*06:02 for the associated risk of HCC after adjustment for other confounders. The adjusted HRs for HCC were 0.45 (0.30-0.68) for DQB1*03:01 (P 5 0.0001) and 2.11 (1.34-3.34) for DQB1*06:02 (P 5 0.0013). After stratification by HCV genotypes, HCV genotype served as an effect modifier for HLA-DQB1 on the risk of HCC. In patients with HCV genotype 1, DQB1*03:01 was a significant protector against HCC, with an adjusted HR of 0.43 (0.23-0.81). On the other hand, DQB1*03:01 was not significantly associated with HCC in patients with HCV non-1 genotypes (P 5 0.2370). Among patients with HCV non-1 genotypes, DQB1*06:02 significantly increased HCC risk, and the adjusted HR was 3.03 (1.18-7.74). However, DQB1*06:02 and HCC were not associated in patients with HCV genotype 1 (P 5 0.1117). The findings suggested that there was an interaction between HCV genotype and HLA-DQB1 on the risk of HCC (P < 0.001). Moreover, in this study, DQB1*03:01 and DQB1*06:02 were not associated with serum HCV RNA and ALT levels at study entry (P > 0.05) (see Supporting Tables S4 and S5 ).
IMPUTATION AND HAPLOTYPE ANALYSES
We performed imputation-based fine mapping of other HLA regions to determine more possible HLA genotypes associated with HCC risk. In total, there were 11 HLA-A alleles, 16 HLA-B alleles, 12 HLA-C alleles, and 15 HLA-DRB1 alleles with allele frequencies >1% successfully imputed. In our analyses, alleles of HLA-A and HLA-C were not significantly associated with the risk of HCC. HLA-B*54:01 significantly differed among HCC cases and controls, with a P value of 0.043 (Supporting Tables S6-S8 ). However, HLA-B*54:01 was not significant on the association of HCC risk after adjustment of other risk factors (P 5 0.0972). DRB1*15:01 conferred a significant risk of HCC, with an odds ratio of 1.96 (1.31-2.93; corrected P 5 0.026) (Supporting Table S9 ).
We then performed haplotype association analysis (Supporting Table S10 ). Haplotypes of DQB1*03:01-DRB1*11:01 and DQB1*06:02-DRB1*15:01 were associated with HCC (P 5 0.024 and 0.002, respectively). However, after correction for multiple testing, DQB1*06:02-DRB1*15:01 was significantly associated with HCC, with an adjusted HR of 2.26 (1.38-3.70; P 5 0.001). Interestingly, DRB1*15:01 also formed a haplotype with another DQB1 allele, DQB1*06:01; but the haplotype DRB1*06:01-DRB1*15:01 showed no association with HCC. Moreover, all three haplotypes carrying DQB1*03:01 (DQB1*03:01-DRB1*11:01, DQB1*03:01-DRB1*12:01, and DQB1*03:01-DRB1* 12:02) showed lower frequencies in HCC, although the associations did not reach the significance level, whereas each of the DRB1 alleles showed no significant association alone. These results support that DQB1 alleles, rather than DRB1 alleles, exhibit primarily susceptible and protective effects.
Discussion
The present study applied a genome-wide approach to discover genetic variants associated with HCC across the whole genome of patients seropositive for anti-HCV but seronegative for HBsAg. We observed an association between a cluster of SNPs in the HLA-DQB1 region and HCC. Because the HLA region is highly polymorphic, we genotyped the DQB1 locus and observed that DQB1*03:01 and DQB1*06:02 were long-term predictors of HCC risk. Notably, the effects of DQB1 and the associated risk of HCC varied by HCV genotypes.
HLA genes are clustered on the short arm of chromosome 6, which are relevant for the regulation of both cellular and innate immunity and highly polymorphic in the human genome. These genes encode molecules that form stable complexes on binding to foreign peptides, and these complexes are presented on cell surfaces. T lymphocytes recognize and respond to antigenic peptide fragments, subsequently initiating a cascade of immune responses to clear foreign antigens. Studies have investigated the associations between HLA genotypes and HCV infection outcomes including HCV RNA clearance and liver disease progression. (22) (23) (24) (25) (26) (27) (28) (29) (30) Most of these studies were conducted on European descendants, (22, (24) (25) (26) 29) but the results were inconsistent, possibly because of varying study designs or ethnicities with various distributions on HLA alleles. DQB1*03:01 has been associated with RNA clearance. (22, (24) (25) (26) 29) Patients with DQB1*03:01 seemed to have a low HCV viral load. (24) However, in our study, DQB1*03:01 and DQB1*06:02 were not associated with serum HCV RNA or ALT levels. Our findings suggest that these host genetic variants were independently associated with HCC, which might provide insights into a more detailed understanding of disease progression.
The effects of HLA genotypes on the development of liver disease in patients with HCV infection are not well established. Most previous studies have used limited numbers of clinical patients with a cross-sectional design and have reported conflicting findings. (24, 26, 27) The Women's Interagency HIV Study reported that DQB1*03:01 had low odds of liver fibrosis, which is consistent with our findings. (24) Our community-based prospective study reports associations between HLA genotypes and HCC risk. We performed highresolution HLA genotyping and determined that (13, 14) ; these studies have reported that the variant near DEPDC5 on chromosome 22 and that near MICA on chromosome 6 were associated with the risk of HCC. (13, 14) However, one of the studies (13) included participants without HCV infection as the control group in the GWAS and replication phase. Interpreting or determining whether the aforementioned variants were associated with susceptibility to infection, viral clearance, inflammation, or liver progression is difficult. Both variants reported in previous GWASs were not designed on our SNP genotyping platform. Thus, we selected the closest SNPs of the two previously identified SNPs to evaluate their associations with HCC risk. We found that the P value was 0.0462 for rs5749334 (closest to rs1012068, DEPDC5) and 2.38 3 10 -5 for rs2523484 (closest to rs2596542, MICA), respectively. Both of them did not pass the significance threshold in the GWAS stage (<8.7 3 10 -8 ) (Supporting Table S11 ). A previous study suggested a protective association between the variant near MICA and HCC in European descendants. (31) Other variants may be present in case of a shared causal variant across Japanese and European populations within this region. The variant near MICA is located within the class I HLA region; thus, the inconsistent results also imply that the HLA region encompasses the complex and extended linkage disequilibrium structure. Limited SNPs could not capture the variations in this region, and direct HLA genotyping might be required. Notably, a GWAS reported that an SNP near the c6orf10 gene, which is very close to the HLA class II region, is significantly associated with liver cirrhosis. (32) In our population, this SNP was associated with HCC but did not pass the threshold P value even after multiple corrections, implying that deep sequencing in this region must be performed. In Supporting Fig. S1 , the SNPs on chromosome 6 reported in a previous GWAS and our eight SNPs showed low correlations with each other, suggesting that the region we found was independently associated with HCV-related HCC. A detailed understanding of this region and liver pathogenesis may facilitate future vaccine development and novel drug discovery.
Our study observed the protective effect of DQB1*03:01 on the risk of HCC only in patients with HCV genotype 1. However, the risk of HCC stratified by DQB1*06:02 was increased in patients with HCV non-1 genotypes. Our data support that hepatocarcinogenesis is associated with virus-host interactions. A study reported that viral strains influenced the associations of certain HLA genotypes with HCV RNA clearance, (23) implying that a virus may develop specific mutations within its genome to escape detection by immune responses. (33) During chronic infection, the viral strains must be strongly adapted to the host immune system to live in the liver cells. In patients with chronic hepatitis B infection, the effects of some SNPs near the HLA region have been reported to contribute to the risk of cirrhosis or HCC and to vary by hepatitis B virus genotypes and mutations. (34, 35) Our study has some limitations. First, the HCV infection time was not known. Most communityresiding patients acquired HCV mainly because of iatrogenic risk factors. (36) Thus, it was difficult for these patients to recall their infection date. Second, most patients in the REVEAL-HCV cohort had no experiences of antiviral treatments because of poor disease awareness and medical accessibility. In Taiwan, the government reimbursed antiviral treatments for patients with chronic hepatitis C until October 2003; when patients had abnormal serum ALT levels (>2 3 upper limit normal) and moderate fibrosis, as assessed through liver biopsy (Metavir F2 or Ishak F3), they could be reimbursed for treatment by the National Health Insurance program. In addition, the antiviral drugs could only be prescribed by hepatologists. In the beginning of antiviral treatment reimbursement, few patients received standard care because invasive liver biopsy was not acceptable for asymptomatic carriers. In a previous report, only 36% of patients were aware of their HCV infection. (37) Among these aware patients, approximately 40% received antiviral treatment, and the side effects were the main barriers to treatment. (37) Thus, in this study, the controls from the REVEAL-HCV cohort had no experience of antiviral treatment. On the other hand, some of the HCC cases from the TLCN may receive interferon-based treatment. The impacts of the SNPs we found on the GWAS phase on the risk of HCC might be underestimated. However, we performed direct genotyping on the HLA-DQB1 locus among the untreated subjects in the REVEAL-HCV cohort to show HLA variants and associated risk for HCC.
Recently, the rapid development of numerous novel drugs has opened new avenues for chronic hepatitis C treatment. The new antiviral drugs, including directacting antivirals and host-targeted agents, are impressive for their high efficacy, short treatment course, oral administration, and high tolerance. (38) In the future, increasing numbers of patients with chronic hepatitis C will have a chance to experience treatment-induced RNA clearance. Moreover, 30% of our patients had spontaneous HCV RNA clearance, and few of them subsequently developed HCC. Evaluating the HLA-DQB1-associated risk of HCC in patients seronegative for HCV RNA in our study is difficult. Future studies must determine the associations between DQB1*03:01 and DQB1*06:02 and the risk of HCC in patients in whom HCV has been successfully cleared by treatment. As hepatitis B virus is endemic in Taiwan, the majority of our participants (all were seronegative for HBsAg) may have been exposed to hepatitis B virus with an occult infection rate of at least 90%.
In conclusion, this study revealed that the genetic variants on the HLA-DQB1 locus are associated with HCV-related HCC. In patients with HCV genotype 1, DQB1*03:01 exerted protective effects against HCC. In contrast, DQB1*06:02 was associated with an increased risk of HCC in patients with HCV non-1 genotypes. The genetic variants provide insights for prioritizing patients to receive novel expensive drugs and intensive monitoring strategies.
